MKC-1
- Generic Name
- MKC-1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16N4O4
- CAS Number
- 125313-92-0
- Unique Ingredient Identifier
- DNZ11VPY7Q
- Indication
Investigated for use/treatment in breast cancer, leukemia (unspecified), lung cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00656461
- Locations
- ๐บ๐ธ
U. of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00607607
- Locations
- ๐จ๐ฆ
Juravinski Cancer Centre, Hamilton, Ontario, Canada
๐จ๐ฆCancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
๐จ๐ฆCredit Valley Hospital, Mississauga, Ontario, Canada
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00568646
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00506402
- Locations
- ๐จ๐ฆ
Princess Margaret Hospital, Toronto, Canada
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00408226
- Locations
- ๐บ๐ธ
University of Iowa, Iowa City, Iowa, United States
๐บ๐ธIndiana University Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00306631
- Locations
- ๐บ๐ธ
IUPUI, Indianapolis, Indiana, United States
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00003755
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00014365
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-10-15
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00016250
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.